Business
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
WATERTOWN, Mass., January 08, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/57371b8c965583707b9ec08933af68e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i0xGFH9b5yZ2Mg4r5gCGgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/57371b8c965583707b9ec08933af68e8","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bPbzWsq8dYejZo_wM0KEjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/57371b8c965583707b9ec08933af68e8","width":1200,"height":401}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV)","length":248,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expanding Immunology Pipeline with New Discovery Program Focused on MRGPRX2 Inhibition Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); On Track to Select a Development Candidate in 2H 2026","length":207,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Advancing EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate; On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026","length":181,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Progressing EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate; On Track to File an IND in 2H 2026","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong Financial Position Supported by Continuing Retained Royalties with Cash Runway Expected to Fund Operations into Fiscal 2029","length":130,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company to Present 2026 Outlook at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:00 PM PT","length":123,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1004,"olType":false},{"type":"text","content":"WATERTOWN, Mass., January 08, 2026--(BUSINESS WIRE)--Enant...